In this video


What makes Biogen's Alzheimer's drug so controversial

The U.S.'s approval of Biogen's Alzheimer's drug Aduhelm was heralded as a triumph in the fight against the memory-robbing disease. But so far, Biogen has reported only a fraction of the expected revenue for Aduhelm. Patients and physicians have been torn over the drug's murky clinical data and its high price tag. Aduhelm's lackluster launch has been costly, forcing Biogen to take measures to keep the drug afloat.
Tue, Jan 4 202211:52 AM EST